NASDAQ:SRTS - Nasdaq - US81728J1097 - Common Stock - Currency: USD
NASDAQ:SRTS (5/28/2025, 8:01:46 PM)
4.84
+0.02 (+0.41%)
The current stock price of SRTS is 4.84 USD. In the past month the price increased by 8.76%. In the past year, price decreased by -10.7%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.62 | 229.69B | ||
ISRG | INTUITIVE SURGICAL INC | 72.3 | 197.99B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.71 | 154.62B | ||
SYK | STRYKER CORP | 30.36 | 145.37B | ||
MDT | MEDTRONIC PLC | 14.77 | 104.19B | ||
BDX | BECTON DICKINSON AND CO | 12.28 | 49.59B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.48 | 44.97B | ||
IDXX | IDEXX LABORATORIES INC | 45.12 | 41.68B | ||
RMD | RESMED INC | 26.96 | 35.89B | ||
DXCM | DEXCOM INC | 52.72 | 34.11B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.47 | 32.58B | ||
STE | STERIS PLC | 26.23 | 24.07B |
Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 35 full-time employees. The company went IPO on 2016-06-03. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
SENSUS HEALTHCARE INC
851 Broken Sound Pkwy NW Ste 215
Boca Raton FLORIDA 33487 US
CEO: Joseph C. Sardano
Employees: 54
Phone: 15619225808
The current stock price of SRTS is 4.84 USD. The price increased by 0.41% in the last trading session.
The exchange symbol of SENSUS HEALTHCARE INC is SRTS and it is listed on the Nasdaq exchange.
SRTS stock is listed on the Nasdaq exchange.
11 analysts have analysed SRTS and the average price target is 12.24 USD. This implies a price increase of 152.89% is expected in the next year compared to the current price of 4.84. Check the SENSUS HEALTHCARE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SENSUS HEALTHCARE INC (SRTS) has a market capitalization of 79.62M USD. This makes SRTS a Micro Cap stock.
SENSUS HEALTHCARE INC (SRTS) currently has 54 employees.
SENSUS HEALTHCARE INC (SRTS) has a support level at 4.76 and a resistance level at 4.85. Check the full technical report for a detailed analysis of SRTS support and resistance levels.
The Revenue of SENSUS HEALTHCARE INC (SRTS) is expected to grow by 5.53% in the next year. Check the estimates tab for more information on the SRTS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SRTS does not pay a dividend.
SENSUS HEALTHCARE INC (SRTS) will report earnings on 2025-08-06, after the market close.
The PE ratio for SENSUS HEALTHCARE INC (SRTS) is 48.4. This is based on the reported non-GAAP earnings per share of 0.1 and the current share price of 4.84 USD. Check the full fundamental report for a full analysis of the valuation metrics for SRTS.
The outstanding short interest for SENSUS HEALTHCARE INC (SRTS) is 5.94% of its float. Check the ownership tab for more information on the SRTS short interest.
ChartMill assigns a technical rating of 2 / 10 to SRTS. When comparing the yearly performance of all stocks, SRTS is a bad performer in the overall market: 63.93% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to SRTS. SRTS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Over the last trailing twelve months SRTS reported a non-GAAP Earnings per Share(EPS) of 0.1. The EPS decreased by -65.52% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 4.56% | ||
ROA | 2.99% | ||
ROE | 3.4% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to SRTS. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -16.87% and a revenue growth 5.53% for SRTS